English|中文
  • Home
  • About Tongli
    Return
    • Our Mission
    • Business operation model
    • Partnership
  • Research & Development
    Return
    • Our current development focus
    • Pipeline
  • News
  • Contact us
  • Home
  • About Tongli
    Return
    • Our Mission
    • Business operation model
    • Partnership
  • Research & Development
    Return
    • Our current development focus
    • Pipeline
  • News
  • Contact us
English|中文
none
Your Current Position:  News
  • TongliBio reaches a strategic partnership with Occam Biolabs, Inc.
    2020-05-02
  • TongliBio announces to complete pre-A round of financing by Tigermed investment group
    2020-04-29
  • TongliBio announces to complete a clinical phase I trial with TL-010 in South Africa
    2019-07-29
  • TongliBio announces to present development of TL-010 as an orphan drug at World Orphan Drug Congress
    2019-04-11
  • TongliBio announcs to receive a clearance letter from the US FDA for its IND application of TL-010
    2018-10-15
  • ​TongliBio announces TL-010 was granted with orphan drug designation by FDA
    2017-07-28
  • TongliBio announces to receive an early investment from two private investment groups including TF capital
    2017-04-05
  • TongliBio is invited to attend the WHO informal consultant meeting Sept.29-30. 2015 in Geneva, Switzerland
    2015-09-29
Follow us:

Email:tl.office@tonglibio.com
Telephone:86-0512-58113269
Company Address:Rm 401, Bldg D, No.1 North Guotai Rd, Zhangjiagang, Suzhou, Jiangsu Province, PRC
苏ICP备13010604号

Verification code *
Submit

COPYRIGHT (©)  Tongli Biomedical Co. (TLB) Reserved 
Technical support: Three to Five Interconnection
TOP